<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9951325</identifier>
<setSpec>0002-5151</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Olalde Carmona, R</dc:author>
<dc:author>Vázquez García, M J</dc:author>
<dc:author>Escárcega Barbosa, D</dc:author>
<dc:author>Juárez, J A</dc:author>
<dc:description xml:lang="en">BACKGROUND Intravenous Immunoglobulin (i.v.Ig) has been advocated as efficacious for Systemic Lupus Erytematosus (SLE) and Lupic Nephritis (LN) using high dosages, propitious a prolonged remission of SLE. MATERIAL AND METHOD We show the case of a male patient 16 years old, with SLE diagnosis until 1993, and LN phase IV. He attend to hospital with a Lupic Crisis, positives ANAs, DNAds, ScL 427, C3 45, C4 13, IgG 179, urinary sediment: leukocytes 30-40 xc, erythrocytes 8-10 xc. Renal failure: BUN 243, seric Cr: 10.16. I.v. Ig administrated 400 mgs k do. And nephrologic assistance, NK. RESULTS There was improvement after infusion, clinical and serological, persisting with renal failure. The mechanism by which i.v. Ig might have effected improvement in this patient was reviewed. CONCLUSION The use in our patient with SLE and LN was satisfactory. Is difficult affirm categorical the outcome or failure of i.v. Ig in patients with SLE, even report founded are only few cases report.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1998 Nov-Dec </dc:date>
<dc:title xml:lang="es">Tratamiento de crisis lúpica con IgIV.</dc:title>
<dc:title xml:lang="en">[Treatment of lupus crisis with IgIV].</dc:title>
<dc:publisher>Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)</dc:publisher>
</metadata>
</record>
</pubmed-document>
